| Oncolytic adenovirus dually expressing interferon beta and membrane-stable CD40 ligand increases polyfunctional CD8+T cells associated with antitumor activity MJ Cantwell, AN Saltos, H Zheng, D Foresman, AA Beg Cancer Research 84 (6_Supplement), 6655-6655, 2024 | | 2024 |
| Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors ML Ibrahim, H Zheng, ML Barlow, Y Latif, Z Chen, X Yu, AA Beg The Journal of Immunology 212 (4), 737-747, 2024 | 2 | 2024 |
| 629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment … AN Saltos, C Arrowood, GM Beasley, J Ronald, G El-Haddad, JE Gray, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | | 2023 |
| Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results. AN Saltos, T Tanvetyanon, BC Creelan, MR Shafique, SJ Antonia, ... Journal of Clinical Oncology 41 (16_suppl), 9125-9125, 2023 | | 2023 |
| Sotorasib, a selective G12C K-RAS inhibitor, modulates the tumor microenvironment to promote TNFα and IFNγ signaling and augment immunotherapy response ML Ibrahim, D Foresman, H Zheng, EB Haura, D Abate-Daga, X Yu, ... Cancer Research 83 (7_Supplement), 3264-3264, 2023 | | 2023 |
| Combination IFNβ and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity H Zheng, X Yu, ML Ibrahim, D Foresman, M Xie, JO Johnson, TA Boyle, ... Cancer immunology research 11 (4), 466-485, 2023 | 5 | 2023 |
| 1130 Investigating macrophage modulation in a murine model of soft tissue sarcoma K Hildebrand, K Hildebrand, F Zemp, CS Arcila, M Monument Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor … H Zheng, S Antonia, MJ Cantwell, X Yu, AA Beg Cancer Research 82 (12_Supplement), 3542-3542, 2022 | | 2022 |
| Defining anti-tumor immune stimulatory mechanisms of MEM-288, a CD40 ligand and IFN-beta dual-transgene armed oncolytic adenovirus H Zheng, CD Powell, S Antonia, MJ Cantwell, BA Perez, AA Beg Cancer Research 81 (13_Supplement), 697-697, 2021 | 1 | 2021 |
| Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity H Zheng, W Dai, S Antonia, MJ Cantwell, AA Beg Cancer Research 80 (16_Supplement), 4578-4578, 2020 | 1 | 2020 |
| Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC). AN Saltos, T Tanvetyanon, BC Creelan, MR Shafique, SJ Antonia, ... Journal of Clinical Oncology 38 (15_suppl), 9567-9567, 2020 | 10 | 2020 |
| Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non–small cell lung cancer JE Gray, A Saltos, T Tanvetyanon, EB Haura, B Creelan, SJ Antonia, ... Clinical Cancer Research 25 (22), 6623-6632, 2019 | 115 | 2019 |
| MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer M Xie, H Zheng, R Madan-Lala, W Dai, NT Gimbrone, Z Chen, F Kinose, ... Cancer research 79 (22), 5812-5825, 2019 | 9 | 2019 |
| Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis T Han, S Jiang, H Zheng, Q Yin, M Xie, MR Little, X Yin, M Chen, SJ Song, ... Nature Communications 10 (1), 3716, 2019 | 26 | 2019 |
| Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results. AN Saltos, T Tanvetyanon, EB Haura, BC Creelan, SJ Antonia, ... Journal of Clinical Oncology 37 (15_suppl), 9073-9073, 2019 | | 2019 |
| Immuno-oncology (IO) drug conjugate concentrates at cells and tumors and enhances survival SR Kaulagari, M Doligalski, A Cohen, H Zheng, V Estrella, A Beg, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 257, 2019 | | 2019 |
| MEK inhibitors potentiate tumor immune surveillance by enhancing cancer cell response of IFNγ M Xie, H Zheng, A Beg Cancer Research 77 (13_Supplement), 5662-5662, 2017 | | 2017 |
| Targeting immune checkpoint therapy to the lung tumor microenvironment AS Cohen, ML Doligalski, H Zheng, NK Tafreshi, V Estrella, N Delva, ... Cancer Research 77 (13_Supplement), 1709-1709, 2017 | | 2017 |
| HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma H Zheng, W Zhao, C Yan, CC Watson, M Massengill, M Xie, C Massengill, ... Clinical Cancer Research 22 (16), 4119-4132, 2016 | 307 | 2016 |
| Nonlinear dose–response relationship between radon exposure and the risk of lung cancer: evidence from a meta-analysis of published observational studies P Duan, C Quan, C Hu, J Zhang, F Xie, X Hu, Z Yu, B Gao, Z Liu, H Zheng, ... European Journal of Cancer Prevention 24 (4), 267-277, 2015 | 32 | 2015 |
